Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Pizzuti

Showing results (41-50 of 120) with videos related to

Pageof 12
Sort By:
Cancers|September 9, 2020
Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized TrialsDaniele Marinelli, Marco Mazzotta, Laura Pizzuti, et al.
Oncotarget|October 6, 2017
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word settingLaura Pizzuti, Clara Natoli, Teresa Gamucci, et al.
Therapeutic Advances in Medical Oncology|August 12, 2024
Breast and cervical cancer in transgender men: literature review and a case reportFrancesca Sofia Di Lisa, Alice Villa, Lorena Filomeno, et al.
International Journal of Molecular Sciences|May 21, 2020
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future PerspectivesGiacomo Barchiesi, Marco Mazzotta, Eriseld Krasniqi, et al.
Breast Cancer Research and Treatment|August 28, 2021
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)Rosalba Torrisi, Raffaella Palumbo, Rita De Sanctis, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 4, 2016
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapyPatrizia Vici, Cristiana Ercolani, Anna Di Benedetto, et al.
International Journal of Molecular Sciences|December 11, 2022
Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA ExplorationEriseld Krasniqi, Frauke Goeman, Claudio Pulito, et al.
Oncotarget|June 2, 2016
The Hippo transducers TAZ/YAP and their target CTGF in male breast cancerAnna Di Benedetto, Marcella Mottolese, Francesca Sperati, et al.
Oncotarget|September 15, 2017
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trialLuca Moscetti, Maria Agnese Fabbri, Clara Natoli, et al.
Breast (Edinburgh, Scotland)|January 6, 2019
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patientsVincenzo Graziano, Antonino Grassadonia, Laura Iezzi, et al.
Pageof 12

Showing results (41-50 of 120) with videos related to

Sort By:
Pageof 12
Cancers|September 9, 2020
Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized TrialsDaniele Marinelli, Marco Mazzotta, Laura Pizzuti, et al.
Oncotarget|October 6, 2017
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word settingLaura Pizzuti, Clara Natoli, Teresa Gamucci, et al.
Therapeutic Advances in Medical Oncology|August 12, 2024
Breast and cervical cancer in transgender men: literature review and a case reportFrancesca Sofia Di Lisa, Alice Villa, Lorena Filomeno, et al.
International Journal of Molecular Sciences|May 21, 2020
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future PerspectivesGiacomo Barchiesi, Marco Mazzotta, Eriseld Krasniqi, et al.
Breast Cancer Research and Treatment|August 28, 2021
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)Rosalba Torrisi, Raffaella Palumbo, Rita De Sanctis, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 4, 2016
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapyPatrizia Vici, Cristiana Ercolani, Anna Di Benedetto, et al.
International Journal of Molecular Sciences|December 11, 2022
Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA ExplorationEriseld Krasniqi, Frauke Goeman, Claudio Pulito, et al.
Oncotarget|June 2, 2016
The Hippo transducers TAZ/YAP and their target CTGF in male breast cancerAnna Di Benedetto, Marcella Mottolese, Francesca Sperati, et al.
Oncotarget|September 15, 2017
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trialLuca Moscetti, Maria Agnese Fabbri, Clara Natoli, et al.
Breast (Edinburgh, Scotland)|January 6, 2019
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patientsVincenzo Graziano, Antonino Grassadonia, Laura Iezzi, et al.
Pageof 12